Your browser doesn't support javascript.
loading
[Graft failure, poor graft function erythroblastopenia: Actualization of definitions, diagnosis and treatment: Guidelines from the SFGM-TC]. / Non-prise de greffe, dysfonctionnement du greffon et érythroblastopénie : mise à jour des définitions, outils diagnostiques et prise en charge : recommandation de la SFGM-TC.
Srour, Micha; Fayard, Amandine; Giannotti, Federica; Giltat, Aurelien; Guenounou, Sarah; Roy, Jean; Schmitt, Justine; Servais, Sophie; Alsuliman, Tamim; Agha, Ibrahim Yakoub; Guillerm, Gaelle.
Affiliation
  • Srour M; Hôpital Huriez, CHRU Lille, maladies du sang, rue Michel-Polonowski, 59000 Lille, France.
  • Fayard A; CHU de Clermont-Ferrand, service hématologie, 1, rue Lucie- et Raymond-Aubrac, 63003 Clermont-Ferrand, France.
  • Giannotti F; HUG, service hématologie, rue Gabrielle-Perret-Gentil, 4, 1205 Genève, Suisse.
  • Giltat A; CHU d'Angers, service hématologie, 4, rue Larrey, 49933 Angers cedex 9, France.
  • Guenounou S; Institut universitaire du cancer de Toulouse-Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex, France.
  • Roy J; Hématologie, 5415, boulevard de l'assomption, QC H1T 2M4 Montréal, Canada.
  • Schmitt J; CHU de Liège, service d'hématologie biologique et d'immuno-hématologie, Liège, Belgique.
  • Servais S; CHU de Liège, service d'hématologie clinique, Liège, Belgique.
  • Alsuliman T; AP-HP, hôpital Saint-Antoine, Sorbonne université, service d'hématologie, Paris, France. Electronic address: tamim.alsuliman@aphp.fr.
  • Agha IY; Université Lille, CHU de Lille, Infininite, Inserm U1286, 59000 Lille, France.
  • Guillerm G; Hôpital Morvan, CHRU Brest, service d'hématologie, 2, avenue Foch, 29609 Brest cedex, France.
Bull Cancer ; 110(2S): S67-S78, 2023 Feb.
Article in Fr | MEDLINE | ID: mdl-36307323
ABSTRACT
In this article, we discuss again the definition, the risk factor and guideline to treat the graft failure, the poor graft function and erythrobalstopenia. Graft failure is a severe but rare complication after hematopoietic cell transplantation (HCT). Despite disparity in the literature, we defined this complication and discussed the factor risks and recommendation for treatment based on new studies. Poor graft function is also a more frequent complication after HCT. New studies will soon be available to prove or not the current recommendation suggested in this article based on therapeutics medicine or cellular therapy. Erythroblastopenia, is a rarer complication post HCT. Despite anticipation for a better choice of compatibility donor/recipient, some patients still suffer from this complication.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Graft vs Host Disease Type of study: Diagnostic_studies / Guideline / Risk_factors_studies Limits: Humans Language: Fr Journal: Bull Cancer Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Graft vs Host Disease Type of study: Diagnostic_studies / Guideline / Risk_factors_studies Limits: Humans Language: Fr Journal: Bull Cancer Year: 2023 Document type: Article Affiliation country:
...